Literature DB >> 16085360

C3a expressed in the central nervous system protects against LPS-induced shock.

Laura Boos1, Alexander J Szalai, Scott R Barnum.   

Abstract

Complement is implicated in the pathogenesis of inflammatory disorders of the central nervous system (CNS), like multiple sclerosis, Alzheimer's disease, and trauma. The anaphylatoxins C3a and C5a are thought to be the major contributors to complement-mediated inflammation in the CNS, likely mediating their effects via their ability to attract and activate leukocytes and common capacity to augment inflammation. For example, in experimental autoimmune encephalomyelitis, the animal model of multiple sclerosis, CNS-specific expression of C3a in C3a/GFAP transgenic mice renders them prone to massive cellular infiltration of the CNS and increases their mortality. In contrast, other studies have suggested that C3a can function in an anti-inflammatory fashion in the CNS, by inducing neurotrophin production and preventing NMDA-mediated neurotoxicity. To further investigate the seemingly paradoxical role of C3a in acute inflammation of the brain, we studied the pathogenesis of endotoxin shock in C3a/GFAP transgenic, C3a receptor-deficient (C3aR-/-) and C3a/GFAPxC3aR-/- mutant mice. Here we report that C3a/GFAP mice were significantly more resistant to endotoxin-induced lethality than wild-type and C3aR-/- mice. Surprisingly, C3a/GFAPxC3aR-/- hybrids were also significantly protected, indicating that C3a exerts its protective anti-inflammatory effect either directly or via an as yet unidentified non-canonical C3aR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085360     DOI: 10.1016/j.neulet.2005.07.015

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  22 in total

Review 1.  Complement in neuroprotection and neurodegeneration.

Authors:  Vijay Yanamadala; Robert M Friedlander
Journal:  Trends Mol Med       Date:  2010-01-28       Impact factor: 11.951

Review 2.  Perspective is everything: an irreverent discussion of CNS-immune system interactions as viewed from different scientific traditions.

Authors:  Monica J Carson; David D Lo
Journal:  Brain Behav Immun       Date:  2007-01-17       Impact factor: 7.217

Review 3.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 4.  The Role of Complement C3a Receptor in Stroke.

Authors:  Saif Ahmad; Kanchan Bhatia; Adam Kindelin; Andrew F Ducruet
Journal:  Neuromolecular Med       Date:  2019-05-17       Impact factor: 3.843

5.  Complement Peptide C3a Promotes Astrocyte Survival in Response to Ischemic Stress.

Authors:  Noriko Shinjyo; Yolanda de Pablo; Milos Pekny; Marcela Pekna
Journal:  Mol Neurobiol       Date:  2015-05-14       Impact factor: 5.590

6.  Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model.

Authors:  Z Shao; T Nishimura; L L K Leung; J Morser
Journal:  J Thromb Haemost       Date:  2015-05-10       Impact factor: 5.824

7.  Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease.

Authors:  Paul B Larkin; Paul J Muchowski
Journal:  J Huntingtons Dis       Date:  2012

8.  Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disorders.

Authors:  Gurudutt Pendyala; Howard S Fox
Journal:  Genome Med       Date:  2010-03-30       Impact factor: 11.117

9.  Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys.

Authors:  Gurudutt Pendyala; Sunia A Trauger; Ewa Kalisiak; Ronald J Ellis; Gary Siuzdak; Howard S Fox
Journal:  J Proteome Res       Date:  2009-05       Impact factor: 4.466

10.  Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease.

Authors:  Jun Zhou; Maria I Fonseca; Karntipa Pisalyaput; Andrea J Tenner
Journal:  J Neurochem       Date:  2008-07-09       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.